Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by JACK A ROTH and IGNACIO IVAN WISTUBA.
JACK A ROTH
Connection Strength
2.102
IGNACIO IVAN WISTUBA
  1. Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer. Clin Cancer Res. 2019 01 01; 25(1):150-157.
    View in: PubMed
    Score: 0.164
  2. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One. 2012; 7(4):e34833.
    View in: PubMed
    Score: 0.105
  3. Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients. Clin Cancer Res. 2011 Sep 01; 17(17):5705-14.
    View in: PubMed
    Score: 0.099
  4. Exponential decay nonlinear regression analysis of patient survival curves: preliminary assessment in non-small cell lung cancer. Lung Cancer. 2011 Feb; 71(2):217-23.
    View in: PubMed
    Score: 0.096
  5. Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Clin Cancer Res. 2008 Jan 01; 14(1):41-7.
    View in: PubMed
    Score: 0.078
  6. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol. 2006 Mar; 1(3):231-9.
    View in: PubMed
    Score: 0.068
  7. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res. 2005 Sep 01; 65(17):7568-72.
    View in: PubMed
    Score: 0.066
  8. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
    View in: PubMed
    Score: 0.062
  9. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun. 2022 04 04; 13(1):1797.
    View in: PubMed
    Score: 0.052
  10. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. J Immunother Cancer. 2022 02; 10(2).
    View in: PubMed
    Score: 0.052
  11. Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection. Lung Cancer. 2022 02; 164:69-75.
    View in: PubMed
    Score: 0.051
  12. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
    View in: PubMed
    Score: 0.048
  13. Elevated NSD3 histone methylation activity drives squamous cell lung cancer. Nature. 2021 02; 590(7846):504-508.
    View in: PubMed
    Score: 0.048
  14. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021 03 08; 39(3):346-360.e7.
    View in: PubMed
    Score: 0.048
  15. Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. J Thorac Oncol. 2021 04; 16(4):583-600.
    View in: PubMed
    Score: 0.048
  16. LKB1/STK11 Expression in Lung Adenocarcinoma and Associations With Patterns of Recurrence. Ann Thorac Surg. 2020 10; 110(4):1131-1138.
    View in: PubMed
    Score: 0.046
  17. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020 09; 15(9):1449-1459.
    View in: PubMed
    Score: 0.046
  18. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. Clin Lung Cancer. 2020 07; 21(4):341-348.
    View in: PubMed
    Score: 0.045
  19. Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities. J Thorac Dis. 2020 Mar; 12(3):329-337.
    View in: PubMed
    Score: 0.045
  20. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer. 2020 04; 1:423-436.
    View in: PubMed
    Score: 0.045
  21. From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later. J Cell Biochem. 2020 Aug; 121(8-9):3986-3999.
    View in: PubMed
    Score: 0.044
  22. The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. Clin Cancer Res. 2020 02 15; 26(4):892-901.
    View in: PubMed
    Score: 0.044
  23. Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells. Oncogene. 2020 01; 39(4):801-813.
    View in: PubMed
    Score: 0.044
  24. Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019 09; 158(3):911-919.e6.
    View in: PubMed
    Score: 0.043
  25. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 06; 14(6):1021-1031.
    View in: PubMed
    Score: 0.042
  26. Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy. Cancer Med. 2018 06; 7(6):2405-2414.
    View in: PubMed
    Score: 0.040
  27. Serum MicroRNA-150 Predicts Prognosis for Early-Stage Non-Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1. Clin Pharmacol Ther. 2018 06; 103(6):1061-1073.
    View in: PubMed
    Score: 0.038
  28. A miR-SNP biomarker linked to an increased lung cancer survival by miRNA-mediated down-regulation of FZD4 expression and Wnt signaling. Sci Rep. 2017 08 22; 7(1):9029.
    View in: PubMed
    Score: 0.038
  29. RNA-dependent protein kinase (PKR) depletes nutrients, inducing phosphorylation of AMP-activated kinase in lung cancer. Oncotarget. 2015 May 10; 6(13):11114-24.
    View in: PubMed
    Score: 0.032
  30. Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer. J Thorac Oncol. 2014 May; 9(5):675-84.
    View in: PubMed
    Score: 0.030
  31. Prognostic significance of combinations of RNA-dependent protein kinase and EphA2 biomarkers for NSCLC. J Thorac Oncol. 2013 Mar; 8(3):301-8.
    View in: PubMed
    Score: 0.028
  32. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2012 May; 7(5):825-32.
    View in: PubMed
    Score: 0.026
  33. Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS One. 2012; 7(2):e31087.
    View in: PubMed
    Score: 0.026
  34. The role of PKR/eIF2a signaling pathway in prognosis of non-small cell lung cancer. PLoS One. 2011; 6(11):e24855.
    View in: PubMed
    Score: 0.025
  35. Activating enhancer-binding protein-2? nucleolar localization predicts poor survival after stage I non-small cell lung cancer resection. Ann Thorac Surg. 2011 Sep; 92(3):1044-50.
    View in: PubMed
    Score: 0.025
  36. Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. J Thorac Oncol. 2010 Dec; 5(12):1894-904.
    View in: PubMed
    Score: 0.024
  37. Prognostic significance of RNA-dependent protein kinase on non-small cell lung cancer patients. Clin Cancer Res. 2010 Nov 15; 16(22):5522-8.
    View in: PubMed
    Score: 0.024
  38. Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects. Mol Cancer. 2009 Oct 24; 8:91.
    View in: PubMed
    Score: 0.022
  39. miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res. 2009 Aug; 7(8):1234-43.
    View in: PubMed
    Score: 0.022
  40. Malignant pleural mesothelioma. J Clin Oncol. 2009 Apr 20; 27(12):2081-90.
    View in: PubMed
    Score: 0.021
  41. Data driven semantic integration of translational lung cancer research at MDAnderson Cancer Center. AMIA Annu Symp Proc. 2008 Nov 06; 927.
    View in: PubMed
    Score: 0.021
  42. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008 Oct 23; 455(7216):1069-75.
    View in: PubMed
    Score: 0.021
  43. Cytoglobin, the newest member of the globin family, functions as a tumor suppressor gene. Cancer Res. 2008 Sep 15; 68(18):7448-56.
    View in: PubMed
    Score: 0.020
  44. A Semantic Web management model for integrative biomedical informatics. PLoS One. 2008 Aug 13; 3(8):e2946.
    View in: PubMed
    Score: 0.020
  45. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007 Dec 06; 450(7171):893-8.
    View in: PubMed
    Score: 0.019
  46. A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res. 2007 Jun 15; 67(12):5889-95.
    View in: PubMed
    Score: 0.019
  47. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res. 2006 Dec 15; 12(24):7329-38.
    View in: PubMed
    Score: 0.018
  48. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005 Mar 02; 97(5):339-46.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.